Higher cement prices help India's UltraTech beat earnings estimates
Consolidated net profit, including gains from its India Cements deal in 2024, was 22.26 billion rupees ($258.11 million) - above the 21.56 billion rupees estimated by analysts, on average, according to data compiled by LSEG.
Standalone net profit for the three months ended June 30 was up 48% on-year.
Cement prices rose about 2% on-year on average in the quarter, according to brokerage Ambit Capital, extending the steady recovery so far this year after last year's slump.
Finance chief Atul Daga said in a post-earnings call that cement prices have continued to improve in July, especially in the South Indian markets, which emerged out of a long pricing lull in April.
'Prices have (been) favorably poised in spite of heavy monsoons,' Daga said.
The company reported a revenue of 212.75 billion rupees, surpassing analysts' estimates of 200.12 billion rupees. However, its consolidated sales volume growth of 9.7% was near the lower side of the 9.6%-17.5% growth range projected by four brokerages.
Heavy rains dampened demand in Maharashtra, Gujarat and Odisha, while geopolitical tensions stalled construction activity in India's northern border states, the company said.
India and Pakistan saw their worst clashes in decades in the quarter, following a deadly attack in Indian Kashmir in April. The April-June period is also a seasonally soft quarter for cement companies, as monsoon showers slow construction.
The company's dealmaking, such as the acquisition of India Cements and Kesoram's cement business, helped in capacity expansion and shielded its volumes from weather-led volatility, analysts have said.
UltraTech shares closed 0.5% higher.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Recorder
6 hours ago
- Business Recorder
Russian rouble, markets await outcome of Putin-Witkoff meeting
MOSCOW: The Russian rouble and markets held their breath on Wednesday as they awaited the outcome of President Vladimir Putin's meeting with U.S. special envoy Steve Witkoff at the Kremlin. Witkoff and Putin had 'useful and constructive' talks, a Kremlin aide Yuri Ushakov said, two days before the expiry of a deadline set by President Donald Trump for Russia to agree to peace in Ukraine or face new sanctions. The rouble was flat at around 80 to the dollar, according to data compiled by LSEG based on over-the-counter quotes. It weakened by 0.2% against China's yuan at the Moscow Stock Exchange. Russia's main stock market index was down 0.15%. 'The market is awaiting the outcome of the meeting between Vladimir Putin and Steve Witkoff,' T-Bank's analysts said. Many analysts believe that the rouble is overvalued and awaiting a trigger to weaken. The Russian currency rallied by up to 45% against the dollar earlier this year, partly thanks to expectations of a thaw in the relationship between Russia and the U.S. as well as hopes for a peaceful settlement in Ukraine. Options on the table for Trump to put more pressure on Russia if Witkoff returns empty-handed include new sanctions against Russia's energy and banking sectors and possible sanctions or trade tariffs on buyers of Russian oil. Kremlin earlier said that Russia had developed an immunity to sanctions thanks to long experience. However, the latest round of U.S. sanctions against a Russian bank, which handled payments for energy, imposed last year, led to the rouble's slide. 'In the coming days, the currency market will be waiting for news from the visit of the U.S. President's special representative and clarification of the situation regarding possible U.S. sanctions,' said PSB Bank's Evgeny Loktykhov.
Business Recorder
9 hours ago
- Business Recorder
Indian drugmaker Divi's misses June-quarter profit view on weak US pricing
India's Divi's Laboratories reported first-quarter profit below estimates on Wednesday, as manufacturers producing generic drugs continued to be negatively impacted by pricing pressures in the key U.S. market, sending shares down 3.3%. The Hyderabad-based company's consolidated net profit rose 26.7% to 5.45 billion rupees ($62 million) for the quarter ended June 30. Analysts, on average, had expected 5.75 billion rupees, as per data compiled by LSEG. Indian generic drugmakers, which get a significant chunk of their revenue from the U.S., have been grappling with weak pricing amid stiff competition in the region. Divi's, one of India's largest manufacturers of active pharmaceutical ingredients (API), has flagged pricing pressure and high competition in its generics business in global markets, adding that it aims to increase its market share by launching molecules as they get off patent. APIs are key chemical components in a drug that produce the intended therapeutic effects. Divi's exports to more than 100 countries, with the U.S. and Europe being its core markets The company's shares were down 2.5% before the news, in tandem with the rest of the pharma stocks on U.S. President Donald Trump's potential tariff threat. India's Pidilite posts higher quarterly profit on strong demand; announces bonus issue The drugmaker's peers Cipla and Dr Reddy's also reported subdued June-quarter sales in the U.S. Revenue from operations for Divi's rose 14% to 24.10 billion rupees, also missing analysts' estimates of 24.56 billion rupees. The company is banking on demand from diabetes and weight-loss drugs manufacturers such as Eli Lilly, who cater to skyrocketing customer demand for the drug in global markets.
Business Recorder
a day ago
- Business Recorder
India's Berger Paints misses quarterly profit view on higher expenses, one-time charge
Berger Paints India reported quarterly profit below analyst estimates on Tuesday, as higher expenses and a one-time charge related to a fire incident weighed. Consolidated net profit shrank 11% to 3.15 billion rupees (about $36 million) in the quarter ended June 30. Analysts, on average, had predicted a profit of 3.62 billion rupees, as per data compiled by LSEG. Berger took a one-time charge of 368.1 million rupees during the quarter. Key context Indian paintmakers have been grappling with soft retail demand. 'The early onset of monsoon played spoilsport this quarter,' CEO Abhijit Roy said in a statement. However, India's largest paintmaker Asian Paints said last month that it sees some 'green shoots' of demand recovery in the sector. It had resorted to discounts in the quarter to buy back customers, while it posted an in-line quarterly profit. Rivals, Akzo Nobel India and Kansai Nerolac posted lower quarterly profit.
